Poland
· Delayed Price · Currency is PLN Molecure Statistics
Total Valuation
Molecure has a market cap or net worth of PLN 169.30 million. The enterprise value is 135.34 million.
| Market Cap | 169.30M |
| Enterprise Value | 135.34M |
Important Dates
The last earnings date was Wednesday, April 30, 2025.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Molecure has 20.20 million shares outstanding. The number of shares has increased by 20.16% in one year.
| Current Share Class | 20.20M |
| Shares Outstanding | 20.20M |
| Shares Change (YoY) | +20.16% |
| Shares Change (QoQ) | -34.20% |
| Owned by Insiders (%) | 3.43% |
| Owned by Institutions (%) | 20.00% |
| Float | 14.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 48.51 |
| PB Ratio | 1.72 |
| P/TBV Ratio | 4.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.57 |
| EV / Sales | 38.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.65 |
Financial Position
The company has a current ratio of 10.28, with a Debt / Equity ratio of 0.07.
| Current Ratio | 10.28 |
| Quick Ratio | 10.28 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.23 |
| Interest Coverage | -427.39 |
Financial Efficiency
Return on equity (ROE) is -30.82% and return on invested capital (ROIC) is -18.60%.
| Return on Equity (ROE) | -30.82% |
| Return on Assets (ROA) | -17.68% |
| Return on Invested Capital (ROIC) | -18.60% |
| Return on Capital Employed (ROCE) | -29.58% |
| Revenue Per Employee | 34,218 |
| Profits Per Employee | -290,524 |
| Employee Count | 102 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.65% in the last 52 weeks. The beta is 2.59, so Molecure's price volatility has been higher than the market average.
| Beta (5Y) | 2.59 |
| 52-Week Price Change | -45.65% |
| 50-Day Moving Average | 8.49 |
| 200-Day Moving Average | 10.83 |
| Relative Strength Index (RSI) | 48.61 |
| Average Volume (20 Days) | 15,782 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Molecure had revenue of PLN 3.49 million and -29.63 million in losses. Loss per share was -1.41.
| Revenue | 3.49M |
| Gross Profit | 172,817 |
| Operating Income | -30.59M |
| Pretax Income | -29.63M |
| Net Income | -29.63M |
| EBITDA | -30.36M |
| EBIT | -30.59M |
| Loss Per Share | -1.41 |
Balance Sheet
The company has 40.66 million in cash and 6.69 million in debt, giving a net cash position of 33.97 million or 1.68 per share.
| Cash & Cash Equivalents | 40.66M |
| Total Debt | 6.69M |
| Net Cash | 33.97M |
| Net Cash Per Share | 1.68 |
| Equity (Book Value) | 98.21M |
| Book Value Per Share | 4.93 |
| Working Capital | 37.52M |
Cash Flow
In the last 12 months, operating cash flow was -28.69 million and capital expenditures -420,981, giving a free cash flow of -29.11 million.
| Operating Cash Flow | -28.69M |
| Capital Expenditures | -420,981 |
| Free Cash Flow | -29.11M |
| FCF Per Share | -1.44 |
Margins
| Gross Margin | 4.95% |
| Operating Margin | -876.48% |
| Pretax Margin | -849.05% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Molecure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.16% |
| Shareholder Yield | -20.16% |
| Earnings Yield | -17.50% |
| FCF Yield | -17.20% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |